• Alias: LT-253 HCl
    • A small-molecule inhibitor of human MTF-1 that induces the expression of MTF-1-dependent tumor suppressor factor KLF4 that subsequently leads to the downregulation of cyclin D1, blocking cell cycle progression and proliferation
    • Also causes reduced expression of genes involved in tumor hypoxia and angiogenesis
    • Currently under investigation in phase 1 clinical trial with solid tumors and AML; phase 2 trial will be performed in NSCLC
    • Preliminary side effects: Fatigue, hypophosphatemia
    (Haroon et al., 2004)
    Other topics in Targeted and Immunotherapy Agents